LIBTAYO® (cemiplimab-rwlc) is now approved for the adjuvant treatment of adult patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation.
Click here to learn more.
Printer-Friendly Version